<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-M0V08YOG</identifier><date>2023</date><creator>Ocvirk, Janja</creator><relation>documents/doc/M/URN_NBN_SI_doc-M0V08YOG_001.pdf</relation><relation>documents/doc/M/URN_NBN_SI_doc-M0V08YOG_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 6-9</format><identifier identifier_type="COBISSID_HOST">141425155</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-M0V08YOG</identifier><language>slv</language><publisher publisher_location="Ljubljana">Katedra za onkologijo</publisher><publisher publisher_location="Ljubljana">Onkološki inštitut</publisher><publisher publisher_location="Ljubljana">Sekcija za internistično onkologijo</publisher><source>Novosti v imunoterapiji 2022</source><rights>InC</rights><subject language_type_id="slv">imunoterapija</subject><subject language_type_id="slv">onkologija</subject><subject language_type_id="slv">onkološko zdravljenje</subject><title>Immunotherapy in oncology in 2022 - moving to early stages</title><title>Imunoterapija v onkologiji v letu 2022 – premik v zgodnje stadije</title></Record>